This post was originally published on this site
Profit slumped in the quarter to $82 million from $133 million a year ago.
It said it was raising its outlook due to strong results in the first nine months and the outlook for the full year.
It now expects sales of $2.25 billion, up from a previous outlook for at least $2.2 billion.
Last month, The Wall Street Journal reported that California-based diagnostics company Bio-Rad Laboratories (NYSE:BIO) was in talks to merge with Qiagen.
